In Canada, cancer is the leading cause of death. More than two in five Canadians can expect to be diagnosed with cancer at some point in their lives. Consequently, oncology is the leading therapeutic class in pharmaceutical sales in the country.
Fortunately, enormous strides have been made in recent years in the identification, diagnosis, and treatment for many cancer types. With innovation accelerating in this critical area of patient care, we examine the current market access landscape in Canada and identify hurdles that exist in providing patients with timely access to leading-edge treatments.
This paper looks at Canada's place in the global launch sequence of new oncology products, discusses precision medicine and companion diagnostics, and examines referral patterns and awareness of CAR T-cell therapies by oncologists using IQVIA's Canadian CAR-T Monitor data.